MedTrace Logo

Effect of Empagliflozin in Patients With eGFR Between 10 and 20 ml/Min/1.73m2

NCT07074418 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2026-01-23

No results posted yet for this study

Summary

The proximal tubule remains the main site for sodium reabsorption in patients with advanced renal failure. The investigators therefore hypothesize that SGLT2i should still exert a significant natriuretic effect in patients with eGFR below 20 ml/min/1.73m2, and therefore should still decrease proteinuria with a potential renal protective effect.

Conditions

  • Chronic Kidney Diseases

Interventions

DRUG

Empagliflozin 10 MG then Placebo

Taking Empagliflozin first

DRUG

Placebo then Empagliflozin 10 MG

Taking the Empagliflozin in second

Sponsors & Collaborators

Principal Investigators

  • Vincent ESNAULT, MD-PHD · CHU NICE

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-30
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07074418 on ClinicalTrials.gov